TScan Therapeutics Reports Positive Phase 1 Results for TSC-101 in Heme Malignancies

Reuters06:30

TScan <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Phase 1 Results for TSC-101 in Heme Malignancies

TScan Therapeutics Inc. has announced updated results from the ongoing ALLOHA™ Phase 1 trial (NCT05473910) of TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The data were presented in a poster session at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition. The trial results indicate that all three TSC-101-treated patients who reached two-year follow-up remained relapse-free, compared to one of four patients in the control arm. TSC-101 was well-tolerated, with no dose-limiting toxicities observed. The company plans to initiate a pivotal study of TSC-101 in the second quarter of 2026, following agreement from the U.S. Food and Drug Administration on the study design. A virtual Key Opinion Leader event discussing these results was scheduled for December 8.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598079-en) on December 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589882206?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-07 06:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589882206","market":"nz","top_or_hot":-1,"title":"TScan Therapeutics Reports Positive Phase 1 Results for TSC-101 in Heme Malignancies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TScan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Phase 1 Results for TSC-101 in Heme Malignancies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TScan Therapeutics Inc. has announced updated results from the ongoing ALLOHA™ Phase 1 trial (NCT05473910) of TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The data were presented in a poster session at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition. The trial results indicate that all three TSC-101-treated patients who reached two-year follow-up remained relapse-free, compared to one of four patients in the control arm. TSC-101 was well-tolerated, with no dose-limiting toxicities observed. The company plans to initiate a pivotal study of TSC-101 in the second quarter of 2026, following agreement from the U.S. Food and Drug Administration on the study design. A virtual Key Opinion Leader event discussing these results was scheduled for December 8.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598079-en) on December 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TScan Therapeutics Reports Positive Phase 1 Results for TSC-101 in Heme Malignancies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTScan Therapeutics Reports Positive Phase 1 Results for TSC-101 in Heme Malignancies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-07 06:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TScan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Phase 1 Results for TSC-101 in Heme Malignancies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TScan Therapeutics Inc. has announced updated results from the ongoing ALLOHA™ Phase 1 trial (NCT05473910) of TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The data were presented in a poster session at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition. The trial results indicate that all three TSC-101-treated patients who reached two-year follow-up remained relapse-free, compared to one of four patients in the control arm. TSC-101 was well-tolerated, with no dose-limiting toxicities observed. The company plans to initiate a pivotal study of TSC-101 in the second quarter of 2026, following agreement from the U.S. Food and Drug Administration on the study design. A virtual Key Opinion Leader event discussing these results was scheduled for December 8.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598079-en) on December 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDL3Hs97p:1","article_id":"2589882206","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589882206","pubTimestamp":1765060219,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TScan Therapeutics Inc. has announced updated results from the ongoing ALLOHA Phase 1 trial  of TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The data were presented in a poster session at the 67th American Society of Hematology  Annual Meeting and Exposition. The trial results indicate that all three TSC-101-treated patients who reached two-year follow-up remained relapse-free, compared to one of four patients in the control arm. TSC-101 was well-tolerated, with no dose-limiting toxicities observed. The company plans to initiate a pivotal study of TSC-101 in the second quarter of 2026, following agreement from the U.S. Food and Drug Administration on the study design. A virtual Key Opinion Leader event discussing these results was scheduled for December 8.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4539":"次新股","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","BK4139":"生物科技","TCRX":"Tscan Therapeutics, Inc.","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所"},"translate_title":"TScan Therapeutics报告TSC-101治疗血红素恶性肿瘤的积极1期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"TCRX":0.9},"content_text":"TScan Therapeutics Reports Positive Phase 1 Results for TSC-101 in Heme Malignancies\n    \n\n        TScan Therapeutics Inc. has announced updated results from the ongoing ALLOHA™ Phase 1 trial (NCT05473910) of TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The data were presented in a poster session at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition. The trial results indicate that all three TSC-101-treated patients who reached two-year follow-up remained relapse-free, compared to one of four patients in the control arm. TSC-101 was well-tolerated, with no dose-limiting toxicities observed. The company plans to initiate a pivotal study of TSC-101 in the second quarter of 2026, following agreement from the U.S. Food and Drug Administration on the study design. A virtual Key Opinion Leader event discussing these results was scheduled for December 8.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598079-en) on December 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589882206","isCrawlerRequest":true}